— Know what they know.
Not Investment Advice
Asset Manager ← All Institutions

Royalty Pharma Sub-Manager, LLC

Q2 2026 · Filed 2026-08-21
Market Value
$303M
+37.9%
Holdings
6
+1
New Purchases
1
Added To
0
Closed
1
Reduced
0
Top 10 Concentration
100.0%
Turnover
33.3%

Top Buys (by % of Portfolio)

SymbolCur %Prior %Chg %Value
KLRA 17.88% 0.00% +17.88% $54M
BHVN 14.44% 11.32% +3.12% $44M

Top Sells (by % of Portfolio)

SymbolCur %Prior %Chg %Value
BCRX 0.00% 16.68% -16.68% $0
CYTK 27.61% 29.44% -1.84% $84M
ZBIO 20.03% 21.27% -1.24% $61M
BCAX 20.03% 21.27% -1.24% $61M

Sector Allocation Over Time

Market Cap Concentration

TierHoldingsValueWeight
Mid Cap 2 $84M 27.6%
Small Cap 4 $219M 72.4%

Portfolio Analytics

Avg Market Cap
$2.7B
Median Market Cap
$1.9B
Avg P/E
—
Median P/E
—
Avg Dividend Yield
—%
Avg Beta
0.46
# Stocks
6
# ETFs / Funds
0

Top Holdings (6 total)

# Symbol % Port Shares Value Avg Price Q/Q Value Chg Share Chg Chg % Status
1 CYTK 27.61% 980,392 $84M $85.19 $19M — —
2 BCAX 20.03% 2,388,150 $61M $25.38 $14M — —
3 ZBIO 20.03% 2,388,150 $61M $25.38 $14M — —
4 KLRA 17.88% 2,455,357 $54M $22.03 — +2,455,357 — NEW
5 BHVN 14.44% 2,936,507 $44M $14.88 $19M — —
6 BCRX —% — — — -$37M -3,846,154 -100.0% SOLD

New Positions

SymbolValue% Port
KLRA $54M 17.88%

Sold Out Positions

SymbolValue% Port
BCRX — —%
View SEC EDGAR Filings for Royalty Pharma Sub-Manager, LLC →

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms